Dyno Therapeutics, A Biotechnology Company Applying Artificial Intelligence (Ai) To Gene Therapy, Today Announced A Collaboration With Novartis To Develop Improved Adeno-Associated Virus (Aav) Vectors For Research, Development, And Commercialization Of Gene Therapies For Ocular Diseases. The Partnership Will Allow The Parties To Utilize Dyno&Rsquo;S Capsidmap&Trade; Artificial Intelligence Platform Along With Novartis Expertise In Gene Therapy Development And Global Commercialization To Deliver Innovative Gene Therapies To Patients With Serious Diseases Of The Eye.&Ldquo;We Are Delighted To Be Collaborating With Novartis,&Rdquo; Stated Eric D. Kelsic, Ph.D., Ceo And Co
